Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score N/A
- Piotroski Score N/A
- Grade Neutral
- Symbol (ENIA)
- Company Enel Américas S.A.
- Price $4.81
- Changes Percentage (0%)
- Change -$0
- Day Low $4.73
- Day High $5.09
- Year High $7.32
Enel Américas S.A., together with its subsidiaries, explores, develops, operates, generates, transfers, transforms, distributes, and sells electricity using hydroelectric and thermal energy sources in Argentina, Brazil, Colombia, and Peru. As of December 31, 2020, it had 11,269 megawatts of installed generation capacity and 25.6 million distribution customers. The company was formerly known as Enersis Américas S.A. and changed its name to Enel Américas S.A. in December 2016. Enel Américas S.A. was founded in 1889 and is headquartered in Santiago, Chile. Enel Américas S.A. operates as a subsidiary of Enel S.p.A.
- Last Earnings 05/02/2022
- Ex-Dividend for 5/16 Dividend 05/24/2022
- Dividend Payable 06/09/2022
- Today N/A
- Next Earnings (Estimated) 08/04/2022
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Buy
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.45
- Trailing P/E Ratio 10.688888888889
- Forward P/E Ratio 10.688888888889
- P/E Growth 10.688888888889
- Net Income $1.13 B
Income Statement
Quarterly
Annual
Latest News of ENIA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Ontario man was suffering schizophrenia years before he killed his parents: defence - Toronto | Globalnews.ca
Kyle Sequeira, who was found not criminally responsible for killing his parents due to mental illness, admitted to an aggravated assault two years prior. Sequeira was intoxicated and suffered from sub...
By Global News | 21 hours ago -
New schizophrenia drug gets FDA approval, taking novel approach to treating brain disorder
The FDA approved a new drug called COBENFY for schizophrenia treatment in adults, offering a novel approach to managing the disorder. This marks a significant advancement in the field after several de...
By Fox News | 21 hours ago -
Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential
FDA approved Bristol Myers Squibb's Cobenfy for schizophrenia in adults, without a boxed warning, signaling a positive outlook. Analysts project high sales for Cobenfy in treating Alzheimer's psychosi...
By Yahoo! Finance | 1 day ago
